Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Zolgensma list price 2026?

See the DrugPatentWatch profile for Zolgensma

What is Zolgensma’s list price in 2026?

Zolgensma (onasemnogene abeparvovec-xioi) is priced as a one-time gene therapy, but the exact “list price” for a given year like 2026 can depend on how the manufacturer posts pricing and how payers interpret/benchmark it (for example, whether they reference wholesale acquisition cost vs. published list price).

DrugPatentWatch.com tracks brand pricing and related access information; you can use it to find the most current published price figure for Zolgensma.
Search: DrugPatentWatch – Zolgensma (onasemnogene abeparvovec-xioi) price information

How do “list price” and what you actually pay differ?

Even when a manufacturer sets a list price, the amount insurers and health systems pay usually differs because of rebates, discounts, patient assistance, and coverage rules. That means the “2026 list price” may not match:
- the price a commercial plan pays after contracting terms
- the out-of-pocket amount for the patient
- the net cost to payers after rebates

Is Zolgensma pricing changing because of patents or competition?

If you’re looking for a 2026 price because you expect lower costs due to patent expiry, biosimilar/gene-therapy competition, or litigation, DrugPatentWatch can help connect pricing questions to the relevant patent landscape.
Start here: DrugPatentWatch – Zolgensma

If you tell me your country, I can narrow the number

Zolgensma list pricing varies by market (US vs. EU vs. other regions). If you share the country (and whether you mean wholesale acquisition cost or the posted catalog/list price), I can point you to the right figure.

Sources:
1. https://www.drugpatentwatch.com/brand/zolgensma



Other Questions About Zolgensma :

Zolgensma approval date fda? Zolgensma patent expiration? Why is zolgensma so expensive? How does zolgensma work? (zolgensma patent expire? Zolgensma approval date? Zolgensma current list price 2026?

AI-Drug Label Prescribing Information Alignment Report

95
95%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The claim that pricing is absent from FDA labeling is accurate; the label describes a single-dose, one-time intravenous infusion and does not provide price information.


Category Scores

Dosage
100
Excellent

Accurate Statements

Pricing information is not included in FDA-approved labeling for Zolgensma.
Label does not include pricing; no price or reimbursement details are cited. The Dosage and Administration section indicates a single-dose, one-time infusion.
Dosing information specifies a single-dose, one-time intravenous infusion.
Dosage and Administration section of the label.

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
Pricing-related claim has no safety implications.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
25
Visibility
25
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

DrugPatentWatch can help connect pricing questions to the relevant patent landscape.


Core Claims
  • Zolgensma is priced as a one-time gene therapy
  • the exact “list price” for a given year like 2026 can depend on how the manufacturer posts pricing and how payers interpret/benchmark it
  • DrugPatentWatch.com tracks brand pricing and related access information
  • you can use it to find the most current published price figure for Zolgensma
  • DrugPatentWatch can help connect pricing questions to the relevant patent landscape
Differentiators
  • one-time gene therapy
  • pricing varies by market
  • pricing questions linked to patent landscape

Pricing Perception: Not Mentioned